Catherine Schulte

“Maybe on reveal, can you just talk through expectations on, you know, when you might hear back from Moldyx on some of these indications, some of them are hitting close to the year mark.”

“As you develop more AI agents and applications, are there examples you would highlight as practice changing for physicians today? One. And second, Tempest has the largest multimodal oncology data set.”

“On food, just given that was the one part of the guide that came down, you talked about delays in China and India. Can you just unpack a bit what you're seeing there and how you expect that to play out going forward?”

“Maybe first, you talked about increased activity in your pipeline, supporting maybe some improved growth in the back half.”

“Maybe first for the mid to high single digit melanoma volume growth for the year, off to a really strong start there with mid-teens growth in 1Q. Should that double digit growth continue in the second quarter with some conservatism baked into the back half, or how should we think about the phasing there?”